Skip to content

The Impact of Continuous Renal Replacement Therapy on the Outcomes of Burn Patients With Early Phase of Sepsis

A Randomized Controlled Trial on the Impact of Early Application of CRRT on the Outcomes of Burn Patients With Early Phase of Sepsis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01501097
Acronym
CRRT
Enrollment
60
Registered
2011-12-29
Start date
2011-12-31
Completion date
Unknown
Last updated
2011-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burns, Sepsis

Brief summary

The purpose of this study is to determine if early application of CRRT will result in an improvement of clinical outcomes of burn patients during the early phase of sepsis

Detailed description

The impact of Continuous Renal Replacement Therapy (CRRT) on the outcomes of patients with sepsis is controversial, and there is no consensus for the timing and dose of CRRT may improve the outcomes. The purpose of this prospective randomized study is to assess the effect of different CRRT intensity (25ml/kg/h or 50ml/kg/h) on the outcomes of burn patients with early phase of sepsis

Interventions

PROCEDUREContinuous Renal Replacement Therapy

Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group

Sponsors

Southwest Hospital, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* patients with documented sepsis * clinically identified focus of infection associated with at least 2 SIRS -criteria and one or more sepsis-induced organ failures within the 24 hours -prior to inclusion * age 18 to 70 years * severe burned patients with 50% \< TBSA \< 85%

Exclusion criteria

* cirrhosis child class C * too high APACHE II & SOFA score at admission * age over 70 years * were presence of a malignant tumor, chronic renal insufficiency (serum creatinine \> 133 µmol/L), moribund state, receiving immunosuppressive therapy or receiving any kind of renal replacement therapy before randomization

Design outcomes

Primary

MeasureTime frameDescription
Changes in serum cytokine concentrations and clearance96 hours0, 6, 12 , 24, 48, 96 hours post CRRT

Secondary

MeasureTime frame
28 and 90 days survival90 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026